December 2019

Management of Targeted Therapy Adverse Effects

January 01, 2020

Directions in Pharmacy

It is impossible to assert that patients will not experience any adverse events while on targeted therapy. Communicating and addressing effective mitigation strategies to ameliorate these adverse events can lead to improved clinical outcomes.

Keynote Speakers at 2019 Directions in Oncology Pharmacy Promote Quality Improvement

December 30, 2019

Directions in Pharmacy

Evelyn Handel, PharmD, BCPS, BCOP, director of drugs & biologics programs at the National Comprehensive Cancer Network, presented the keynote address, which was developed in collaboration with Emily Mackler, PharmD, BCOP, of the Michigan Oncology Quality Consortium in Ann Arbor.

Infusion Pharmacist Expertise Vital in Helping Manage IG Shortages, Ensuring Right Drug Gets to the Right Patient at the Right Dose

December 29, 2019

Directions in Pharmacy

Perceived as the new “wonder drug,” immunoglobulin (IG) is a go-to therapy for healthcare providers seeking to bolster their patients’ immune systems; however, as demand grows, particularly for oncology and off-label indications, the supply can’t keep pace.

Current and Future Considerations for Oncology Biosimilars in 2020

December 28, 2019

Directions in Pharmacy

The US health care system expects 2020 to be a year of major cost savings, in part because of the projected significant traction from 3 major biosimilars for rituximab (Rituxan), bevacizumab (Avastin), and trastuzumab (Herceptin), which accounted for a total of $19.4 billion in sales in 2018.

The Hidden Value Proposition for Institutional Oncology Specialty Pharmacy

December 26, 2019

Directions in Pharmacy

The growth area for pharmacy revenue is increasingly apparent in the specialty space, a trend driven by the approvals of new oncology agents with characteristics that are ideal for the specialty pharmacy setting.

Patient Activation, Good Communication, and Shared Decision Making Are Critical in Chronic Lymphocytic Leukemia

December 23, 2019

Directions in Pharmacy

The second session at the 2019 Directions in Oncology Pharmacy™ conference discussed emerging clinical options for patients who have chronic lymphocytic leukemia (CLL), with a special emphasis on the pharmacist’s role.

Oral Therapies for Hormone Receptor – Positive Breast Cancers

December 23, 2019

Directions in Pharmacy

The recent development of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, as well as alpelisib (Piqray), a phosphoinositide 3-kinase (PI3K) inhibitor, has changed the way patients with HR-positive MBC are treated.

From the Chairman

December 18, 2019

Directions in Pharmacy

"As 2019 comes to a close and we head into 2020, the anticancer treatment landscape continues to expand, as does the role of pharmacists in the patient care continuum."